Journal article
Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis
Abstract
BACKGROUND: Secukinumab is an anti-IL-17A monoclonal antibody approved for the treatment of moderate-to-severe psoriasis in adult patients. Despite its favourable safety and efficacy profile in clinical trials, some patients in clinical practice fail to respond adequately to the approved maintenance regimen of 300 mg subcutaneous monthly. Some clinicians manage these patients by using off-label high-dose secukinumab regimens, which include …
Authors
Phung M; Ighani A; Georgakopoulos JR; Vender R; Giroux L; Lansang P; Yeung J
Journal
Journal of Cutaneous Medicine and Surgery, Vol. 23, No. 4, pp. 391–393
Publisher
SAGE Publications
Publication Date
July 2019
DOI
10.1177/1203475419843118
ISSN
1203-4754